Global Microbiome Partnering Terms and Agreements 2010 to 2023


The Global Microbiome Partnering Terms and Agreements 2010-2023 report provides comprehensive understanding and unprecedented access to the microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
June 2023
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Microbiome Partnering Terms and Agreements 2010-2023 report provides an understanding and access to the microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.


  • Trends in microbiome partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Microbiome partnering contract documents
  • Top microbiome deals by value


The Global Microbiome Partnering Terms and Agreements 2010-2023 report provides an understanding and access to the microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.


The report provides a detailed understanding and analysis of how and why companies enter microbiome partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors microbiome technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 


This report provides details of the latest microbiome, oligonucletides including aptamers agreements announced in the healthcare sectors.  


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of all microbiome partnering deals announced since 2010 including financial terms where available including over 250 links to online deal records of actual microbiome partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.


Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?


The initial chapters of this report provide an orientation of microbiome dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in microbiome dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.


Chapter 3 provides a review of the leading microbiome deals since 2010. Deals are listed by headline value, signed by big pharma, most active microbiome dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive listing of the top 25 most active companies in microbiome dealmaking with a brief summary followed by a comprehensive listing of microbiome deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.


Chapter 5 provides a comprehensive and detailed review of microbiome partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive and detailed review of microbiome partnering deals signed and announced since Jan 2010. The chapter is organized by specific microbiome technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In addition, a comprehensive appendix is provided organized by microbiome partnering company A-Z, deal type definitions and microbiome partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in microbiome partnering and dealmaking since 2010.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of microbiome technologies and products.


Report scope


Global Microbiome Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to microbiome trends and structure of deals entered into by leading companies worldwide.


Global Microbiome Partnering Terms and Agreements includes:


  • Trends in microbiome dealmaking in the biopharma industry since 2010
  • Access to headline, upfront, milestone and royalty data
  • Access to over 250 microbiome deals
  • The leading microbiome deals by value since 2010
  • Most active microbiome dealmakers since 2010
  • The leading microbiome partnering resources


 In Global Microbiome Partnering Terms and Agreements, the available contracts are listed by:


  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

Global Microbiome Partnering Terms and Agreements provides the reader with the following key benefits:


  • In-depth understanding of microbiome deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 250 actual microbiome deals entered into by the world’s biopharma companies, together with real world clause examples
  • Full listing of  microbiome deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading microbiome deals by value since 2010
  • Identify the most active microbiome dealmakers since 2010
  • Detailed access to actual microbiome contracts enter into by the leading 25 bigpharma
  • Insight into the terms included in microbiome agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in microbiome dealmaking


2.1. Introduction
2.2. Microbiome partnering over the years
2.3. Most active microbiome dealmakers
2.4. Microbiome partnering by deal type
2.5. Microbiome partnering by therapy area
2.6. Deal terms for microbiome partnering
2.6.1 Microbiome partnering headline values
2.6.2 Microbiome deal upfront payments
2.6.3 Microbiome deal milestone payments
2.6.4 Microbiome royalty rates


Chapter 3 – Leading microbiome deals


3.1. Introduction
3.2. Top microbiome deals by value


Chapter 4 – Most active microbiome dealmakers


4.1. Introduction
4.2. Most active microbiome dealmakers
4.3. Most active microbiome partnering company profiles


Chapter 5 – Microbiome contracts dealmaking directory


5.1. Introduction
5.2. Microbiome contracts dealmaking directory


Chapter 6 – Microbiome dealmaking by technology type




Appendix 1 – Microbiome deals by company A-Z

Appendix 2 – Microbiome deals by stage of development

Appendix 3 – Microbiome deals by deal type

Appendix 4 – Microbiome deals by therapy area

Deal type definitions

Further reading on dealmaking


About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering


Table of figures

Figure 1: Microbiome partnering since 2010
Figure 2: Active microbiome dealmaking activity since 2010
Figure 3: Microbiome partnering by deal type since 2010
Figure 4: Microbiome partnering by disease type since 2010
Figure 5: Microbiome deals with a headline value
Figure 6: Microbiome deals with an upfront value
Figure 7: Microbiome deals with a milestone value
Figure 8: Microbiome deals with a royalty rate value
Figure 9: Top microbiome deals by value since 2010
Figure 10: Most active microbiome dealmakers since 2010

Pricing options

  • $3,995: single-user
  • $5,745: multi-user
  • $10,995: single site license
  • $17,995: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

4D Pharma, 9 Meters Biopharma, Aarhus University, Abbott Laboratories, Abbvie, ADL Bionatur Solutions, ADM, Agricultural Research Organization, AiCuris, AIDS Clinical Trials Group, Alimentary Health, Allergan, ALS Association, Amag Pharmaceuticals, American Skin Association, American Type Culture Collection (ATCC), Ancilia Biosciences, AnimalBiome, AntibioTx, Arc Bio, Archer Daniels Midland Company, Arena Pharmaceuticals, Argonne National Laboratory, Ariana Pharma, Arranta Bio, Artizan Biosciences, Assembly Biosciences, AstraZeneca, Ateria Health, Aurealis Therapeutics, Azitra, Bacthera, BASF, Bayer, Bayer CropScience, Bayer Healthcare, Baylor College of Medicine, Baylor Miraca Genetics Laboratories, BCD Bioscience, Beam Therapeutics, Bertin Pharma, Bill and Melinda Gates Foundation, Bio-Me, Bio-Rad Laboratories, BIOASTER, Biocodex Microbiota Foundation, Biocogent, Biocore, Biofortis, Biohaven Pharmaceuticals, BiomeBank, Biomecite Diagnostics, Biomedical Advanced Research and Development Authority, Biomica, Biomillenia, Biomodels, BiomX, BionX Medical Technologies, Bio Palette, Biosortia Pharmaceuticals, BitBiome, Bloom Science, Boehringer Ingelheim, Boston University School of Medicine, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Brown University, Cancer Research UK, CARB-X, Carbiotix, Cargill, Cedars-Sinai Medical Center, Centers for Disease Control and Prevention, Centre Leon Berard, Centre National de la Recherche Scientifique, Centro Sperimentale del Latte, Children's Hospital Boston, Circuit Clinical, Clalit Health Services, CN Bio, Columbia University, Columbia University Medical Center, Commense, Companion PBx, Compass Minerals Plant Nutrition, ConsortiaTX, COPD Foundation, CoreBiome, Cornell University, CosmosID, Crohn's and Colitis Foundation of America, CryoXtract, CSIR - Institute of Microbial Technology, Dana-Farber Cancer Institute, DayTwo, DDL Diagnostic Laboratory, Debiopharm, Defense Advanced Research Projects Agency, Department of Health and Human Services, Dermala, Diversigen, DuPont, DuPont Pharmaceuticals, DuPont Pioneer, Eagle Genomics, EcoMetrix, Elanco, Eligo Bioscience, Emory University, Emulate, EnBiotix, Enterome Bioscience, EpiBiome, European Commission, Evah, Evelo Biosciences, Evogene, Evolve BioSystems, Evotec, Evvy, ExeGi Pharma, Federation Bio, Felix Biotechnology, Ferring Pharmaceuticals, Finch Therapeutics, Florida International University, Food Marble Digestive Health, Forsyth Institute, Fred Hutchinson Cancer Research Center, French National Institute for Agricultural Research, Fundacion Progreso y Salud, Galmed Pharmaceuticals, Genentech, General Automation Lab Technologies, Genetic Analysis, Genewiz, Genome and Company, GenomeQuest, Georges Francois Leclerc Center, German Cryo, GI Innovation, Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline, Glycosyn, Gnubiotics Sciences, Greenteaspoon, Hackensack Meridian Health, Hadassah Medical Center, Hamilton Company, Harvard Medical School, Harvard School of Public Health, Harvard T.H. Chan School of Public Health, Harvard University, Health Canada, Helomics, HLH BioPharma Vertriebs, Holobiome, Horizon Europe, Hospital of University of Strasbourg, Hudson Institute of Medical Research, Human Longevity, Hy Laboratories, IBM, iGenomix, Illumina, Immuron, Impact NRS, Innovate Biopharmaceuticals, Inserm, Inspirotec, Institut De Recherche Pour Le Developpement (IRD), Institute For Life Science Entrepreneurship (ILSE), Institut Gustave Roussy, Institut National Recherche Agronomique, International Centre for Diarrhoeal Disease Research, International Flavors and Fragrances, Intract Pharma, Intralytix, Ipsen, ISOThrive, Jackson Laboratory, Janssen Biotech, Janssen Human Microbiome Institute, Janssen Research & Development, Janssen Therapeutics, J Craig Venter Institute, Jennewein Biotechnologie, Johns Hopkins University, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, JSR, Juntendo University, Kaleido Biosciences, Kallyope, Kantonsspital St. Gallen, Karolinska Institute, Keio Gijuku University, Kenneth Rainin Foundation (KRF), Kindstar Globalgene Technology, King's College Hospital, Kings College London, L'Oreal, Latham BioPharm Group, Lawrence Livermore National Laboratory, Leiden University, Leidos, Les Laboratoires Servier, LNC, Locus Biosciences, Loop Genomics, Loreal, Lupus Research Alliance, Lurie Children's Hospital of Chicago, Lysando, MaaT Pharma, Macrogen, Mainz Biomed, Marrone Bio Innovations, Mars Petcare, Maruho, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Mawi DNA Technologies, Mayo Clinic, MD Anderson Cancer Center, Medical College of Wisconsin, Medical University of Graz, Melanoma Research Alliance, Memorial Sloan Kettering Cancer Center, Merck KGaA, Metabiomics, MetaboGen, Metabolon, Metagenics, Metanome, Micreos, Microba Life Sciences, Microbiome Insights, MicroBiome Therapeutics, Microbiome Therapeutics Innovation Group, Microbiotica, MicroGenDX, Micronoma, Microsoft, Microviable Therapeutics, Midnight Health, MilliporeSigma, MiNiSV, Monsanto, MRM Health, MSD, MyBiotics Pharma, National Cancer Center of Japan, National Eczema Association, National Institute for Biotechnology in the Negev, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, National Organization for Rare Disorders, National Psoriasis Foundation, National Science Foundation, Nestle Health Science, Norgen Biotek, Northeastern University, Northwestern University, North Zealand University Hospital, Norwegian University of Science, Novome Biotechnologies, NuBiyota, Nutricion, Nutrilinea, NYU Langone Medical Center, Oklahoma Medical Research Foundation, Oncodesign, Oncology Venture, One Codex, OpenBiome, OpGen, OptiBiotix, Origin Biosciences, Osel, OSEO, Oslo University Hospital, Owlstone Medical, Pancreatic Cancer Collective, PanTheryx, Pathogen and Microbiome Institute, Pathogenica, Penn State Microbiome Center, Pennsylvania State University, Persephone Biosciences, Pfizer, Pharmabiota, Pharmatest Services, Pierre Fabre, Plan France Relance, Precision Biomonitoring, Prescient Medical, Psomagen, Puma Biotechnology, Purdue Research Foundation, Purdue University, PureTech Health, Qiagen, Quadram Institute, Quark Venture, Quimica Europea, Rebiotix, ReproCell, Research Council of Norway, RIKEN Research Institute, Ritter Pharmaceuticals, Roswell Park Cancer Institute, Ruggles Family Foundation, Rutgers University, SACCO, Salix Pharmaceuticals, Samsung Biologics, Sanofi, SATT Lutech, Second Genome, Sequential Skin, Seres Therapeutics, Servatus Biopharmaceuticals, Seven Bridges Genomics, Sheba Medical Center, Siolta Therapeutics, Sirenas, Skive Hospital, SkyePharma, Solarea Bio, Sonic Healthcare, Spanish National Cancer Research Centre, Stanford Cancer Institute, Stanford University School of Medicine, Statens Serum Institute, Sun Genomics, Swiss Integrative Center for Human Health, Symbiotix Biotherapies, Synergie Lyon Cancer, Synlogic, Synthetic Biologics, Taconic Biosciences, Takeda Pharmaceutical, Tata Chemicals, Tel Aviv University, Texas Children’s Hospital, The BioCollective, The Healthy Aging Company, The Innovation Fund, The Parker Institute For Cancer Immunotherapy, The Regents of the University of California, Thermo Fisher Scientific, Tokyo Medical and Dental University, Toulouse University Hospital, Transgene, Transnetyx, Tsinghua University, uBiome, UCB, Unilever, UNION Therapeutics, Universite catholique de Louvain, University College Cork, University College Hospital, Ibadan, University Medical Center Utrecht, University of Adelaide, University of Alberta, University of British Columbia, University of Buffalo, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Cape Town, University of Chicago, University of Cincinnati, University of Colorado, University of Heidelberg, University of Houston, University of Illinois, University of Lausanne, University of Manchester, University of Maryland, University of Maryland Institute for Genome Sciences (IGS), University of Maryland School of Medicine, University of Maryland Ventures, University of Massachusetts Medical School, University of Miami, University of Michigan, University of Minnesota, University of Nebraska, University of New South Wales, University of Oslo, University of Pennsylvania, University of Pittsburgh, University of Queensland, University of Rhode Island, University of Sheffield, University of South Alabama (USA) Mitchell Cancer Institute, University of South Carolina, University of Texas, University of Verona, University of Virginia, University of Washington, University Paris Diderot, University Pierre Marie Curie, Valbiotis, Vanderbilt University, Vedanta Biosciences, Venture Life, Vertex Pharmaceuticals, Viome, Virginia Catalyst, Virginia Commonwealth University, Washington University in St Louis, Weizmann Institute, Wellcome Trust, Western Connecticut Health Network, Xbiome, Xycrobe Therapeutics, Yale School of Medicine, Yale University, Yeda Research and Development Company, Yili Industrial Group, Zymo Research

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.